Cohort experience in 39 psychiatric outpatients with high doses of an enteric-coated weekly formulation of fluoxetine

Clinical Drug Investigation

Volumn 22, Issue 3, 2002, Pages 173-179

  Buongiorno, Paul A ^a   Plewes, John M ^b   Wilson, Michael G ^c  

^a Lilly Research Laboratories ^*  (United States)

^b ELI LILLY AND COMPANY   (United States)

^c BUTLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; FLUOXETINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DEPRESSION; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; ENTERIC COATED TABLET; FEMALE; HUMAN; MALE; OUTPATIENT; PRIORITY JOURNAL; REMISSION; SIDE EFFECT;

EID: 0036211430     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200222030-00004     Document Type: Article

References (12)

1. Long-term treatment of depression
2. Adequacy and duration of antidepressant treatment in primary care
3. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression
4. Once-weekly fluoxetine
5. Plasma-level response relationships with fluoxetine and zimelidine
6. Weekly fluoxetine controls symptoms of depression
7. Fluoxetine and norfluoxetine serum concentrations and clinical response in weekly versus daily dosing
8. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder
9. Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder
10. Inhibition and induction of human cytochrome P450 (CYP) enzymes
11. Practice guideline for the treatment of patients with major depressive disorder (Revision)